Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:RLYP's 30-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RLYP Guru Trades in Q4 2015

Chuck Royce 407,700 sh (+34.55%)
» More
Q1 2016

RLYP Guru Trades in Q1 2016

Chuck Royce 467,700 sh (+14.72%)
» More
Q2 2016

RLYP Guru Trades in Q2 2016

Chuck Royce 583,700 sh (+24.80%)
» More
Q3 2016

RLYP Guru Trades in Q3 2016

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:RLYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:BPMC, NAS:ARRY, NAS:CORT, NAS:BGNE, NAS:LXRX, NAS:RGEN, NAS:INVA, NYSE:EBS, NAS:LOXO, NAS:SRPT, NAS:ONCE, NAS:GBT, NAS:DBVT, OTCPK:BVNRY, OTCPK:SOLTF, NAS:AAAP, NAS:DERM, NAS:FOLD, NYSE:CBM, NAS:HALO » details
Traded in other countries:0RY.Germany,
Headquarter Location:USA
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $36.15
EPS (TTM) $ -5.77
Short Percentage of Float21.34%
52-Week Range $10.26 - 32.12
Shares Outstanding (Mil)44.88

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 26 64 166 357
EPS ($) -6.20 -5.64 -4.24 -3.26
EPS without NRI ($) -6.20 -5.64 -4.24 -3.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:RLYP

Headlines

Articles On GuruFocus.com
Royce Micro-Cap Fund Annual Letter to Shareholders Mar 13 2016 
Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon Oct 25 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 

More From Other Websites
FDA Rejects AstraZeneca’s Hyperkalemia Drug (AZN, RLYP) Mar 17 2017
AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment Mar 17 2017
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal... Sep 02 2016
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa Sep 01 2016
Galenica commences Tender Offer for Relypsa Aug 03 2016
Relypsa Inc. Acquisition May Not Be in the Best Interests of RLYP Shareholders Jul 25 2016
RELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Relypsa, Inc. (RLYP)... Jul 25 2016
U.S. Biotech Relypsa Acquired By Galencia For $1.53B (RLYP) Jul 22 2016
RELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe... Jul 22 2016
Ryan & Maniskas, LLP Announces Investigation of Relypsa, Inc. Jul 22 2016
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of... Jul 21 2016
Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal Jul 21 2016
Relypsa Getting Acquired By Swiss Partner Seeking U.S. Entry Jul 21 2016
BBP: An Outperforming Biotechnology ETF Jul 21 2016
Investors Scour Big Pharma M&A Scene for Next Big Takeover Jul 21 2016
Why Shares of Relypsa Are Soaring Today Jul 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)